MIR1825

Summary

MIR1825 (microRNA 1825, HGNC:35389) is a microRNA gene on chromosome 20q11.21.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 100302183 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:35389
Approved symbol	MIR1825
Name	microRNA 1825
Location	20q11.21
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-1825
Ensembl gene	ENSG00000284125
Ensembl biotype	miRNA
Entrez	100302183
RNAcentral	URS000075E057 — miRNA, 53 nt, 3 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000408740

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000408740 — 1 exons

Exon	Start	End
ENSE00001565375	32237795	32237847

Expression profiles

Bgee: expression breadth tissue_specific, 4 present calls, max score 71.20.

Top tissues by expression

4 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	71.20	gold quality
lymph node	UBERON:0000029	67.19	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	59.27	gold quality
hypothalamus	UBERON:0001898	52.65	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 7)

• we provide evidence that the tumor-suppressive microRNA miR-1825 controls KLF2 expression. Reporter gene analyses revealed that both microRNAs directly targeted the 3’-untranslated region of KLF2 messenger RNA. These data demonstrated that miR-1825 expression in serum of human glioma was associated with tumorigenesis and miR-1825 may be used as a biomarker for identification of the pathological grade of glioma. (PMID:28475008)
• Data indicate a microRNA-1825/TBCB/TUBA4A pathway as a putative pathogenic cascade in both familial ALS (fALS) and both sporadic (sALS). (PMID:30030593)
• Upregulation of miR-1825 inhibits the progression of glioblastoma by suppressing CDK14 though Wnt/beta-catenin signaling pathway. (PMID:32605563)
• [Study on the expression of microRNA-1825 in serum of pre-operative and post-operative patients with breast cancer]. (PMID:34034413)
• MiR-182-5p Is Upregulated in Hepatic Tissues from a Diet-Induced NAFLD/NASH/HCC C57BL/6J Mouse Model and Modulates Cyld and Foxo1 Expression. (PMID:37298191)
• Hypoxia-induced tumor exosomes promote angiogenesis through miR-1825/TSC2/mTOR axis in oral squamous cell carcinoma. (PMID:37449548)
• Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax. (PMID:38528641)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.